




Original Article

Yoga as an Add-on Therapy in Parkinson's Disease: A Single Group Open-label Trial

Pooja Mailankody¹, Nitish Kamble¹, Amitabh Bhattacharya¹ , G.S. Shubha Bhat¹, Thamodharan Arumugam¹, K. Thennarasu², Rashmi Arasappa³, Shivarama Varambally³, Ravi Yadav¹  and Pramod Kumar Pal¹ 

¹Department of Neurology, National Institute of Mental Health & Neuro Sciences, Bangalore, Karnataka, India, ²Department of Biostatistics, National Institute of Mental Health & Neuro Sciences, Bangalore, Karnataka, India and ³Department of Psychiatry, National Institute of Mental Health & Neuro Sciences, Bangalore, Karnataka, India

ABSTRACT: Objective: We aimed to evaluate the effect of yoga on motor and non-motor symptoms and cortical excitability in patients with Parkinson's disease (PD). **Methods:** We prospectively evaluated 17 patients with PD at baseline, after one month of conventional care, and after one month of supervised yoga sessions. The motor and non-motor symptoms were evaluated using the Unified Parkinson's disease Rating Scale (motor part III), Hoehn and Yahr stage, Montreal Cognitive Assessment, Hamilton depression rating scale, Hamilton anxiety rating scale, non-motor symptoms questionnaire and World Health Organization quality of life questionnaire. Transcranial magnetic stimulation was used to record resting motor threshold, central motor conduction time, ipsilateral silent period (iSP), contralateral silent period (cSP), short interval intracortical inhibition (SICI), and intracortical facilitation. **Results:** The mean age of the patients was 55.5 ± 10.8 years, with a mean duration of illness of 4.0 ± 2.5 years. The postural stability of the patients significantly improved following yoga (0.59 ± 0.5 to 0.18 ± 0.4 , $p = 0.039$). There was a significant reduction in the cSP from baseline (138.07 ± 27.5 ms) to 4 weeks of yoga therapy (116.94 ± 18.2 ms, $p = 0.004$). In addition, a significant reduction in SICI was observed after four weeks of yoga therapy (0.22 ± 0.10) to (0.46 ± 0.23), $p = 0.004$). **Conclusion:** Yoga intervention can significantly improve postural stability in patients with PD. A significant reduction of cSP and SICI suggests a reduction in GABAergic neurotransmission following yoga therapy that may underlie the improvement observed in postural stability. **Clinicaltrials.gov identifier:** CTRI/2019/02/017564

Résumé: Le yoga comme traitement d'appoint de la maladie de Parkinson : résultats d'un essai non à l'insu, mené dans un seul groupe.

Objectif : L'étude visait à évaluer l'effet du yoga sur les symptômes moteurs et non moteurs de la maladie de Parkinson (MP) ainsi que sur l'excitabilité corticale chez des patients atteints. **Méthode :** Il s'agit d'une étude prospective, réalisée chez 17 patients souffrant de la MP, qui ont été évalués au début, au bout d'un mois de soins usuels et d'un mois de séances supervisées de yoga. Les symptômes moteurs et non moteurs ont été évalués à l'aide de l'échelle Unified Parkinson's disease Rating Scale (UPDRS, partie III, résultats moteurs), de l'instrument de stadification Hoehn and Yahr (H&Y), du test Montreal Cognitive Assessment (MoCA), de l'échelle de dépression d'Hamilton (HAM-D), de l'échelle d'anxiété d'Hamilton (HAM-A), du questionnaire sur les symptômes non moteurs (NMS) et du questionnaire de l'Organisation mondiale de la Santé sur la qualité de vie (QOL). L'enregistrement du seuil moteur au repos (RMT), du temps de conduction motrice centrale (CMCT), de la période silencieuse homolatérale (iSP), de la période silencieuse controlatérale (cSP), de l'inhibition intracorticale à intervalles courts (SICI) et de la facilitation intracorticale (ICF) a été effectué à l'aide de la stimulation magnétique transcrânienne. **Résultats :** L'âge moyen des patients était de $55,5 \pm 10,8$ ans, et la durée moyenne de la maladie, de $4,0 \pm 2,5$ ans. La stabilité posturale des patients s'est améliorée de manière significative après le yoga ($0,59 \pm ,5$ à $0,18 \pm 0,4$; $p = 0,039$). Une réduction significative de la cSP, depuis le début ($138,07 \pm 27,5$ ms) jusqu'à 4 semaine de traitement par le yoga ($116,94 \pm 18,2$ ms; $p = 0,004$), a aussi été observée. Il en a été de même pour la SICI après 4 semaine de traitement par le yoga ($0,22 \pm 0,10$ à $0,46 \pm 0,23$; $p = 0,004$). **Conclusion :** L'intervention par le yoga peut améliorer sensiblement la stabilité posturale chez les patients atteints de la MP. Quant à la réduction importante de la cSP et de la SICI, elle donne à penser à une diminution de la neurotransmission gabaergique après le traitement par le yoga, qui pourrait sous-tendre l'amélioration de la stabilité posturale.

Keywords: Parkinson's disease; resting motor threshold; short interval intracortical inhibition; silent period; transcranial magnetic stimulation; yoga

(Received 25 October 2023; final revisions submitted 13 March 2024; date of acceptance 15 March 2024; First Published online 25 March 2024)

Corresponding author: Pramod Kumar Pal; Email: palpramod@hotmail.com

Pooja Mailankody and Nitish Kamble both authors contributed equally to the manuscript. Hence both are to be considered as first authors.

Cite this article: Mailankody P, Kamble N, Bhattacharya A, Shubha Bhat GS, Arumugam T, Thennarasu K, Arasappa R, Varambally S, Yadav R, and Pal PK. (2025) Yoga as an Add-on Therapy in Parkinson's Disease: A Single Group Open-label Trial. *The Canadian Journal of Neurological Sciences* 52: 102–109, <https://doi.org/10.1017/cjn.2024.43>

© The Author(s), 2024. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation.

Introduction

Parkinson's disease (PD) is a neurodegenerative disease characterized by slowly progressive rigidity, tremor, bradykinesia, and postural imbalance due to the depletion of dopamine in the brain.¹ Patients with PD also have several other features like anxiety, depression, psychosis, constipation, bladder disturbances, sleep abnormalities and anosmia which are considered as 'non-motor' symptoms.² Pharmacotherapy with dopaminergic drugs and deep brain stimulation are the currently available treatment options.¹

Yoga is a combination of physical exercise and mindfulness. Habitual physical exercise has been known to increase dopamine release. Compared to patients with a sedentary lifestyle, those who regularly exercise have better motor and non-motor functions.³ Yoga increases the release of brain-derived neurotrophic factor, which has a role in neurogenesis and synaptic plasticity.^{4,5} This can potentially result in reconstitution of basal ganglia function. Yoga can potentially improve autonomic dysfunction in patients with PD by increasing parasympathetic activity and reducing sympathetic tone.⁶⁻⁸ In a recent meta-analysis, the benefit of yoga was found to be comparable or even superior to exercise in patients with PD.⁹

Transcranial magnetic stimulation (TMS) has been used to study cortical excitability. The TMS studies in PD, especially with regard to silent period (SP) and short interval intracortical inhibition (SICI) have yielded conflicting results.¹⁰⁻¹² These abnormal parameters are normalized by levodopa.¹⁰ The effect of exercise on cortical excitability is also well recognized.¹³ Govindaraj et al. observed changes in TMS parameters, especially SICI and SP, after yoga in healthy individuals. Their pilot study found that yoga modulates GABA-B receptor-mediated cortical inhibition.¹⁴ However, to the best of our knowledge, the effect of yoga on cortical excitability in PD has not been evaluated.

Despite having a strong rationale, yoga studies in PD have failed to show significant improvement in the core motor features.¹⁵ However, the practice of yoga may help in improving balance, decreasing falls, and alleviating depression and anxiety in PD as per available literature.¹⁶⁻¹⁸

Hence, we aimed to evaluate the effect of yoga on motor and non-motor symptoms, cortical excitability, inhibitory and facilitatory properties of the brain in patients with PD.

Methods

Subjects

This prospective single group open-label study was undertaken by the departments of Neurology and Psychiatry at the National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India. The study was registered under the Clinical Trials Registry India (CTRI) (CTRI/2019/02/017564) and was approved by the Institute ethics committee (IEC No.NIMHANS/IEC (BS & NS DIV.) 15th Meeting/2018). All the participants gave written informed consent. Eighteen consecutive patients with PD and motor fluctuations were included in the study. The diagnosis of PD was based on the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.¹⁹

All the patients were on stable dosages of anti-PD medications for at least six weeks before recruitment. Patients with PD on treatment suffering from 'wearing off,' 'delayed ON,' and 'no ON' were considered to have motor fluctuations.²⁰ Patients with severe cognitive deficits, severe spondylotic disease, or arthritis, which may prevent them from undergoing yoga sessions, and patients who had undergone deep brain stimulation for PD were excluded

from the study. Demographic and clinical details were recorded. At baseline, all eighteen patients underwent detailed clinical evaluation. These patients continued to be on conventional treatment (levodopa-carbidopa or dopa agonist as prescribed by the treating Neurologist) for the next month and were reassessed clinically. Subsequently, these patients underwent supervised yoga sessions (with a validated yoga module for PD²¹ for one month (three sessions per week for a total of 4 weeks, each session of 45 minutes), in addition to conventional treatment. The yoga sessions were carried out in the medication ON state. Following this, they were assessed again clinically the next day after completing one month of supervised yoga session (mean duration = 31.35 ± 1.37 days; range - 29-33 days).

Twelve of the 18 patients underwent TMS in the medication OFF state at baseline and after yoga therapy (day after the last yoga session). One patient did not come for follow-up after the baseline assessment and hence was excluded from the analysis (Figure 1). The TMS parameters of the patients ($n = 12$) were compared with those of age and gender-matched healthy controls ($n = 12$) obtained as part of another study by the same team (DST-CSRI. No.SR/CSRI/49/2016).

Clinical assessment

The severity of motor symptoms was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS motor part III), the stage of the disease by Hoehn and Yahr stage and the non-motor symptoms were assessed using the Montreal Cognitive Assessment for cognitive assessment, Hamilton depression rating scale for depression, Hamilton anxiety rating scale for anxiety, non-motor symptoms questionnaire (NMS questionnaire) and World Health Organization quality of life questionnaire (QOL questionnaire). UPDRS motor part III was assessed both in the OFF and ON states. The medication OFF state was defined as at least 12 hours after the last dose of levodopa-carbidopa combination or 18 hours after the last dose of dopamine agonist.²² The medication ON state was determined to have the best improvement in motor symptoms following 1.5 times the usual morning dose of levodopa-carbidopa combination. This was around 60 to 90 minutes after the tablet intake.

Transcranial magnetic stimulation (TMS)

TMS was done using Bistim² system that combines two Magstim 200² stimulators with a hand-held figure of eight coil. Procedure and measurements were carried out following the IFCN committee with all the precautions.²³ TMS was carried out with patients sitting on the chair comfortably. The motor cortex contralateral to the most clinically affected side was stimulated after identifying the optimal scalp position or the hotspot. The motor response (motor evoked potential, MEP) was recorded on the first dorsal interosseus (FDI) muscle on the most affected side using two Ag-AgCl electrodes placed in a belly-tendon montage. The intensity of the stimulus was increased by 5% to obtain a satisfactory MEP. Resting motor threshold (RMT), central motor conduction time (CMCT), ipsilateral silent period (iSP), contralateral silent period (cSP), SICI, and intracortical facilitation (ICF) were recorded.

The RMT was defined as minimal stimulus intensity required to elicit peak-to-peak MEP of at least 50 μ v amplitude in the relaxed FDI during 50% of the ten consecutive trials and expressed in percentage. CMCT (expressed in msec) was calculated as a difference in MEP latency obtained by cortical and cervical spine




Figure 1. Flow diagram of the study.

stimulation. cSP was obtained by stimulating the motor cortex at suprathreshold stimulus (120% of the RMT) during partial contraction of the FDI muscle, whereas for iSP the stimulus intensity was 100% of the total stimulator output on a fully contracted FDI muscle. SICI and ICF were measured as a ratio between the MEP amplitude obtained using two consecutive stimuli (conditioning stimulus and test stimulus) separated by an interstimulus interval (ISI) to the MEP amplitude obtained after test stimulus. The conditioning stimulus was 80% of the RMT, and the test stimulus was 120% of the RMT. For SICI recording, the ISI was 2 msec, and for ICF it was 10 msec. The age and gender-matched healthy controls also underwent the same procedure. The details of the TMS methods are published elsewhere.²⁴

Outcomes

The primary outcome assessed was to look for changes in the UPDRS motor scores (Part III) in the OFF and ON states following four weeks of yoga therapy. The secondary outcomes of the study were to look for changes in the non-motor symptoms and the TMS parameters.

Statistical methods

Based on the percentage change in UPDRS part III motor scores in a drug trial provided by Schrag et al. (effect size = 0.83) sample size was calculated to be 14 with 80% power and 5% type 1 error. Expecting a dropout of 20%, the sample size was estimated to be 18.²⁵ Data were analyzed with the Statistical Software for Social Sciences (SPSS) version 22. Shapiro Wilk's test was used to test the normality of the data. For data that followed a normal distribution, RM-ANOVA was used to compare the scores between the three time points. Non-parametric test- Friedman test followed by Wilcoxon signed ranks test was carried out when the data did not follow the normative distribution. Paired samples *t*-test was carried out to compare TMS parameters before and after yoga. Correlations were calculated with Spearman's

correlation for non-parametric variables. McNemar test was done for comparison of gait and postural stability subscores in UPDRS as all the patients had scores of 0 or 1. A *p* value less than 0.05 was considered significant.

Results

Demographic and clinical details (Table 1)

A total of 18 patients (15 male and three female) with PD were recruited. One patient (male) did not come for further visits after baseline assessment and hence was excluded from the analysis. The mean age and duration of illness were 55.5 ± 10.8 years and 4.0 ± 2.5 years, respectively. Levodopa equivalent daily dose (LEDD) was 580.3 ± 318.9 mg.

Effect of yoga on the motor and non-motor symptoms (Tables 1 and 2)

Motor parameters assessed with UPDRS part III, depression, anxiety, and quality of life did not change significantly after the intervention. The individual components of UPDRS motor part-III rigidity, tremor, bradykinesia, gait and postural stability scores were compared between the three time points. The postural stability subscore (component of UPDRS part III) of patients significantly improved following yoga (0.59 ± 0.5 to 0.18 ± 0.4 , $p = 0.039$). A small but significant improvement was noted in the H & Y stage of PD (Baseline 2.08 ± 0.54 , post yoga 1.94 ± 0.46 ; $p = 0.04$)

Comparison of TMS parameters between the cases and healthy subjects

The patients with PD had a significantly longer cSP when compared to that of healthy subjects (Patients- 138.07 ± 27.46 ms, HC- 86.29 ± 26.11 ms, $p = 0.0001$). SICI was significantly enhanced (suggesting stronger inhibition) in patients with PD compared to healthy subjects (Patients- 0.22 ± 0.10 , HC- 0.52 ± 0.30 , $p = 0.004$). The ICF was significantly lower in

Table 1. Motor scores in patients with PD at baseline, interim (after 1 month of conventional care) and post (after 1 month of yoga)

Motor scores	Baseline	Interim	Post-yoga	p value
UPDRS-III OFF	26.06 ± 7.75	25.00 ± 10.83	21.65 ± 8.40	0.23
UPDRS-III ON	15.53 ± 5.70	14.88 ± 5.54	12.18 ± 4.56	0.18
H & Y	2.08 ± 0.54	2.12 ± 0.45	1.94 ± 0.46	0.040
Delta UPDRS	10.529 ± 4.9132	10.118 ± 9.1712	9.471 ± 5.6138	0.239
RT OFF	3.59 ± 2.830	3.18 ± 2.651	2.88 ± 2.522	0.449
PT OFF	1.82 ± 1.380	2.41 ± 1.622	1.76 ± 1.300	0.115
Rigidity OFF	12.53 ± 3.986	12.65 ± 4.999	10.88 ± 4.196	0.137
Bradykinesia OFF	9.47 ± 4.048	8.82 ± 4.275	7.94 ± 3.864	0.125
Body bradykinesia	1.94 ± 0.659	1.94 ± 0.556	1.65 ± 0.702	0.202
Arising from chair	0.47 ± 0.624	0.53 ± 0.624	0.35 ± 0.493	0.459
Posture	0.59 ± 0.507	0.71 ± 0.470	0.65 ± 0.493	0.717
Gait	0.94 ± 0.243	0.94 ± 0.429	0.65 ± 0.493	0.016*
Postural stability	0.59 ± 0.507	0.59 ± 0.507	0.18 ± 0.393	0.012*

Note: UPDRS = Unified Parkinson’s disease rating scale, H & Y = Hoehn and Yahr stage, PD = Parkinson’s disease, RT = rest tremor, PT = postural tremor, Delta UPDRS denotes the change in UPDRS from OFF to ON stating that values are expressed as mean +/- standard deviation.

Significant values are expressed in bold.

*McNemar test was used further to compare between baseline versus interim scores and interim versus post Yoga scores for gait and postural stability. The postural stability score post yoga was significantly less compared to the interim score ($p = 0.039$). Nevertheless, the postural stability score did not change significantly during the interim assessment as compared to the baseline ($p = 1$).

Table 2. Non-motor symptoms in patients with PD at baseline, interim (after 1 month of conventional care) and post (after 1 month of yoga)

Nonmotor scores	Baseline	Interim	Post	p value
MOCA	26.75 ± 2.41	27.0 ± 3.10	26.75 ± 3.1	0.510
HAM A	9.64 ± 4.98	8.88 ± 5.49	7.76 ± 7.22	0.392
HAM D	9.17 ± 6.39	7.41 ± 6.70	6.70 ± 6.97	0.510
NMS	6.00 ± 3.89	4.50 ± 3.37	4.52 ± 3.06	0.691
QOL	101.44 ± 15.37	94.23 ± 17.81	98.65 ± 11.67	0.462

Note: MOCA = Montreal Cognitive Assessment; HAM A = Hamilton Anxiety scale; HAM- D = Hamilton Depression scale; NMS = Nonmotor symptoms; QOL = Quality of life.

patients when compared to healthy subjects (Patients- 0.34 ± 0.23 , HC- 2.13 ± 1.14 , $p = 0.0001$). No significant difference was observed between the patients and controls for RMT, CMCT, and iSP (Table 3).

Effect of yoga on the TMS parameters (Table 3)

Following yoga, a statistically significant difference was noted in cSP and SICI. There was a reduction in cSP from a baseline of 138.07 ± 27.46 ms to 116.94 ± 18.2 ms after yoga ($p = 0.004$). (Table 3, Figure 2). SICI value increased from a baseline of 0.22 ± 0.10 to 0.46 ± 0.23 after yoga ($p = 0.004$) (Table 3, Figure 3). A non-significant improvement in ICF was also observed following yoga.

Correlation results

Spearman’s correlation was carried out to look for a correlation between TMS parameters and motor scores. There was a significant negative correlation of SICI with the total rigidity

Table 3. Transcranial magnetic stimulation parameters of the patients before and after yoga

	Pre-Yoga (N = 12)	Post Yoga (N = 12)	Healthy Controls	Pre vs Post (p value)	Pre vs Controls
RMT (%)	38.67 ± 4.42	38.17 ± 2.85	44.17 ± 8.12	0.477	0.054
CMCT (ms)	7.57 ± 1.71	7.73 ± 1.34	7.02 ± 1.03	0.585	0.350
cSP (ms)	138.07 ± 27.46	116.94 ± 18.2	86.29 ± 26.11	0.004	0.0001
iSP (ms)	34.39 ± 17.20	33.22 ± 9.75	28.8 ± 8.63	0.702	0.329
SICI (%)	0.22 ± 0.10	0.46 ± 0.23	0.52 ± 0.30	0.004	0.004
ICF (%)	0.34 ± 0.23	0.45 ± 0.32	2.13 ± 1.14	0.199	0.0001

Note: CMCT = central motor conduction time; cSP = contralateral silent period; HC = healthy control; ICF = intracortical facilitation; iSP = ipsilateral silent period; ms = millisecond; RMT = resting motor threshold; SICI = short interval intracortical inhibition. Significant values are expressed in bold.

scores measured during the OFF state at the baseline ($r = -0.80$, $p = 0.00$) (Table 4).

Discussion

The effect of yoga on cortical excitability in patients with PD was evaluated for the first time in this study. The postural stability item subscore on the UPDRS part III of the patients significantly improved following yoga (0.59 ± 0.5 to 0.18 ± 0.4 , $p = 0.039$). TMS parameters such as cSP and SICI also improved significantly following four weeks of yoga.

Effect of yoga on the motor and non-motor symptoms

A significant change was observed for the postural stability scores and H & Y stage in patients with PD following yoga. The




Figure 2. Bar graphs showing the contralateral silent period (cSP) in patients with Parkinson’s disease before and after yoga.




Figure 3. Bar graphs showing the short interval intracortical inhibition (SICI) in patients with Parkinson’s disease before and after yoga. MEP = motor evoked potential.

Table 4. Correlation of TMS parameters with the motor scores

TMS		RT	PT	Rigidity	Bradykinesia	Posture	Gait	Postural stability	UPDRSIII
RMT	<i>r</i>	-0.64	-0.60	0.10	0.37	-0.39	0.31	0.06	-0.23
	<i>p</i> value	0.03	0.04	0.75	0.24	0.21	0.33	0.86	0.47
CMCT	<i>r</i>	-0.29	-0.23	0.37	0.42	-0.44	-0.09	0.08	-0.13
	<i>p</i> value	0.36	0.48	0.24	0.18	0.16	0.79	0.80	0.68
cSP	<i>r</i>	0.36	-0.19	0.29	0.02	0.20	0.13	0.31	0.27
	<i>p</i> value	0.25	0.56	0.36	0.95	0.52	0.68	0.33	0.39
iSP	<i>r</i>	-0.23	0.31	-0.50	-0.30	-0.10	-0.48	-0.42	-0.35
	<i>p</i> value	0.47	0.33	0.10	0.34	0.75	0.11	0.18	0.26
SICI	<i>r</i>	0.00	0.09	-0.80	-0.56	-0.18	-0.26	-0.51	-0.35
	<i>p</i> value	0.99	0.78	0.00	0.06	0.57	0.41	0.09	0.26
ICF	<i>r</i>	0.01	0.31	-0.54	-0.47	-0.05	-0.31	-0.53	-0.17
	<i>p</i> value	0.96	0.32	0.07	0.12	0.87	0.33	0.07	0.61

Note: TMS = transcranial magnetic stimulation; *r* = correlation co-efficient, Spearman's rho; CMCT = central motor conduction time; cSP = contralateral silent period; ICF = intracortical facilitation; iSP = ipsilateral silent period; RMT = resting motor threshold; SICI = short interval intracortical inhibition; RT = rest tremor; PT = postural tremor; UPDRS = Unified Parkinson's disease rating scale.

Significant values are expressed in bold.

improvement in H & Y staging could be due to an improvement observed in the postural stability subscore on the UPDRS part III scale. The lack of improvement in rigidity, tremor, or bradykinesia was not surprising given that none of the other studies showed any significant improvement in these scores.^{16,17} The significant improvement in depression and anxiety observed in other studies^{15,16} was not seen in our study. However, the duration of intervention was much shorter in our study (4 weeks) compared to that of certain other studies (8 weeks and 12 weeks).¹⁶⁻¹⁸ Lower baseline scores for depression and anxiety and shorter duration of yoga practice probably account for the lack of significant change after the intervention in our study group.

The improvement in postural instability after yoga mirrors the observation made by other groups.^{17,18,26-29} Elangovan et al., in a randomized controlled trial (RCT), objectively evaluated the effect of "Hatha yoga" on postural stability during stance and gait kinematics in twenty patients with PD. They found significant improvement in static balance in patients with PD following 12 weeks of yoga practice. Nevertheless, changes in gait and joint flexibility were not statistically significant.²⁹

Cherup et al. compared yoga practice with a proprioceptive training program in an RCT and found that patients with PD had significant improvement in balance and proprioception after 12 weeks of yoga.²⁷ Myers et al. found that the patients with PD had better responses and anticipatory movements to stimuli applied from outside after yoga.¹⁸ Patients with PD had more confidence in balance and ability to manage falls after yoga than the control group.¹⁷ Colgrove et al. found a decline in falls by 25% in the yoga group.^{26,30} Though the scales used to assess postural instability differed, most of the studies found yoga useful for postural stability. The improvement of postural instability with yoga is noteworthy because current therapeutic approaches in PD lack effective measures to address this problem. Currently, neither pharmacotherapy nor DBS can provide satisfactory improvement in postural stability.^{31,32} It should be noted that all the studies using yoga as an intervention including our study, have been carried out in patients with early PD (H & Y stage 1 to 3).^{18,27} Hence, yoga has a role in early PD as an add on to levodopa. In addition, yoga may be

indicated in patients with postural instability not responsive to levodopa. The role of yoga in advanced PD and in those whose motor symptoms are poorly responsive to levodopa needs to be determined in future studies.

Effect of yoga on cortical excitability and its implications

A reduction in cSP and SICI following yoga suggests a decrease of GABAergic neurotransmission in the brain.^{33,34} cSP is mediated by GABA-B receptors, whereas SICI is mediated by GABA-A receptors. This suggests that yoga may work through restoring the balance by reducing GABAergic systems. However, 4-week therapy may be inadequate and warrants a longer duration of yoga therapy to demonstrate its effectiveness. Magnetic resonance spectroscopic (MRS) imaging studies in patients as well as brain tissue studies and animal models suggest involvement in GABA in the pathogenesis of PD.³⁵⁻³⁷ GABA is the main inhibitory neurotransmitter in the brain and alteration in GABA levels has been mainly implicated in the axial symptoms of PD.³⁷ The SICI was significantly higher in patients with PD than healthy controls.¹¹ In comparison, some studies found SICI to be significantly lower in patients with PD.¹⁰⁻¹² This finding could be due to younger age and earlier age of onset in their study.¹¹ One recent study has shown enhanced SICI in patients with PD.³⁸ The differences observed between various studies could be due to the TMS protocols employed, sample size, disease duration, etc.³⁸ cSP duration was prolonged in our study that reduced significantly following the yoga intervention. This is in contrast to the findings of Govindaraj et al. who showed prolonged cSP following yoga in healthy individuals and not in patients with PD. Our study shows that there is a significant inhibition observed in patients with PD which tends to normalize following yoga intervention.

Structural MRI studies have found that the gray matter density and cortical thickness in several areas, including cingulate gyrus, superior frontal gyrus, inferior parietal lobule, insula, medial frontal gyrus, precentral gyrus, parahippocampal gyrus, superior temporal gyrus, occipital gyrus, and cerebellum are greater in Yoga practitioners.³⁹ Hence, it is not surprising to note changes in

cortical excitability following yoga. Interestingly, Passman et al. found that patients with PD rely more on cortical areas than subcortical areas for dynamic balancing.⁴⁰ When there are problems in static balance in healthy subjects, the premotor cortex, supplementary motor area, and prefrontal cortex were found to be activated.⁴¹

Several other groups have assessed the role of yoga in PD. All these studies, including ours, have small sample sizes. The assessment was carried out only at ON state^{16,42} and other studies did not even mention whether the evaluation was carried out at ON or OFF state.^{17,26,43} We assessed the patients both at OFF and ON state and hence could assess whether yoga could produce a change in response to the drug. To the best of our knowledge, our study is the first to evaluate yoga's effect on cortical excitability objectively. The yoga module we used has been validated.²¹

The major limitations of our study are lack of double blinding and lack of randomization. A recent study of the natural history and progression of PD by Cilia et al. found that more than 50% of the clinical response to levodopa is due to the long-duration response, which is the sustained motor response that is found for several days even after stopping the treatment.⁴⁴ Our assessment of 'OFF' after 12 hours of stopping levodopa and 18 hours of stopping dopamine agonist may therefore be inadequate to assess disease severity and progression.

Conclusions

The postural stability of patients with Parkinson's disease (PD) improved significantly after four weeks of supervised yoga sessions. However, the other motor or non-motor scores did not improve significantly after yoga. The significant improvement of the cSP and SICI suggests a potential disease-modifying effect of yoga in PD. The inverse correlation of SICI with rigidity also suggests that yoga has a therapeutic implication in the treatment of PD. It is to be noted that this is a short-term study and that longer duration of yoga practice may be needed to produce clinically significant changes in patients with PD. Longer randomized controlled trials with larger sample sizes will be required for more conclusive evidence.

Data availability. Data will be available on request.

Acknowledgments. Department of Science and Technology/ Science and Technology of Yoga and Meditation (DST/SATYAM/2017/76(G) and DST-CSRI. No.SR/CSRI/49/2016.

Author contributions. **PM:** Conceptualization, organization, execution, statistical analysis, writing of first draft

NK: Organization, execution, manuscript review and critique

AB: Organization, execution

SB: Organization, execution

TA: Organization, execution

KT: Statistical analysis

RA: Organization, execution

SV: Conceptualization, supervision, manuscript review and critique

RY: Conceptualization, supervision, manuscript review and critique

PKP: Conceptualization, supervision, manuscript review and critique

Funding statement. Department of Science and Technology/ Science and Technology of Yoga and Meditation (DST/SATYAM/2017/76(G) and DST-CSRI. No.SR/CSRI/49/2016.

Competing interests. The authors declare that they have no competing interests.

Ethics. The authors confirm that they have received the approval of the Institute Ethics committee (IEC No.NIMHANS/IEC (BS & NS DIV.) 15th Meeting/2018). Written informed consent was obtained from the patients.

References

- Jankovic J. Parkinson's disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatry*. 2008;79:368–76. DOI: [10.1136/jnnp.2007.131045](https://doi.org/10.1136/jnnp.2007.131045).
- Tagliati M, Chaudhuri K, Pagano G. Prevalence of non-motor symptoms in Parkinson's disease: a systematic review with meta-analysis. *Neurology*. 2014;82:82.
- Sacheli MA, Murray DK, Vafai N, et al. Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. *Mov Disord*. 2018;33:1945–50. DOI: [10.1002/mds.27498](https://doi.org/10.1002/mds.27498).
- Govindaraj R, Karmani S, Varambally S, Gangadhar BN. Yoga and physical exercise - a review and comparison. *Int Rev Psychiatry*. 2016;28:242–53. DOI: [10.3109/09540261.2016.1160878](https://doi.org/10.3109/09540261.2016.1160878).
- Lee M, Moon W, Kim J. Effect of yoga on pain, brain-derived neurotrophic factor, and serotonin in premenopausal women with chronic low back pain. *Evid Based Complement Alternat Med*. 2014;2014, 203173. DOI: [10.1155/2014/203173](https://doi.org/10.1155/2014/203173)
- Bowman AJ, Clayton RH, Murray A, Reed JW, Subhan MM, Ford GA. Effects of aerobic exercise training and yoga on the baroreflex in healthy elderly persons. *Eur J Clin Invest*. 1997;27:443–9. DOI: [10.1046/j.1365-2362.1997.1340681.x](https://doi.org/10.1046/j.1365-2362.1997.1340681.x).
- Sathyaprabha TN, Satishchandra P, Pradhan C, et al. Modulation of cardiac autonomic balance with adjuvant yoga therapy in patients with refractory epilepsy. *Epilepsy Behav*. 2008;12:245–52. DOI: [10.1016/j.yebeh.2007.09.006](https://doi.org/10.1016/j.yebeh.2007.09.006).
- Orimo S, Ghebremedhin E, Gelpi E. Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD? *Cell Tissue Res*. 2018;373:267–86. DOI: [10.1007/s00441-018-2851-9](https://doi.org/10.1007/s00441-018-2851-9).
- Suárez-Iglesias D, Santos L, Sanchez-Lastra MA, Ayán C. Systematic review and meta-analysis of randomised controlled trials on the effects of yoga in people with Parkinson's disease. *Disabil Rehabil*. 2022;44:6210–29. DOI: [10.1080/09638288.2021.1966522](https://doi.org/10.1080/09638288.2021.1966522).
- Cantello R, Tarletti R, Civardi C. Transcranial magnetic stimulation and Parkinson's disease. *Brain Res Brain Res Rev*. 2002;38:309–27. DOI: [10.1016/s0165-0173\(01\)00158-8](https://doi.org/10.1016/s0165-0173(01)00158-8).
- Bhattacharya A, Kamble N, Yadav R, Stezin A, Pal PK. Abnormal intracortical functions in Parkinson's disease with rapid eye movement sleep behaviour disorder. *Can J Neurol Sci*. 2022;49:672–7. DOI: [10.1017/cjn.2021.206](https://doi.org/10.1017/cjn.2021.206).
- Ammann C, Dileone M, Pagge C, et al. Cortical disinhibition in Parkinson's disease. *Brain*. 2020;143:3408–21. DOI: [10.1093/brain/awaa274](https://doi.org/10.1093/brain/awaa274).
- Forrester LW, Hanley DF, Macko RF. Effects of treadmill exercise on transcranial magnetic stimulation-induced excitability to quadriceps after stroke. *Arch Phys Med Rehabil*. 2006;87:229–34. DOI: [10.1016/j.apmr.2005.10.016](https://doi.org/10.1016/j.apmr.2005.10.016).
- Govindaraj R, Mehta UM, Kumar V, Varambally S, Thirthalli J, Gangadhar BN. Effect of yoga on cortical inhibition in healthy individuals: a pilot study using transcranial magnetic stimulation. *Brain Stimul*. 2018;11:1401–3. DOI: [10.1016/j.brs.2018.08.017](https://doi.org/10.1016/j.brs.2018.08.017).
- Mailankody P, Varambally S, Thennarasu K, Pal PK. The rationale of yoga in Parkinson's disease: a critical review. *Neurol India*. 2021;69:1165–75. DOI: [10.4103/0028-3886.329545](https://doi.org/10.4103/0028-3886.329545).
- Kwok JYY, Kwan JCY, Auyeung M, et al. Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: a randomized clinical trial. *JAMA Neurol*. 2019;76:755–63. DOI: [10.1001/jamaneurol.2019.0534](https://doi.org/10.1001/jamaneurol.2019.0534).
- Van Puymbroeck M, Walter AA, Hawkins BL, et al. Functional improvements in Parkinson's disease following a randomized trial of yoga. *Evid Based Complement Alternat Med*. 2018;2018:8516351. DOI: [10.1155/2018/8516351](https://doi.org/10.1155/2018/8516351).

18. Myers PS, Harrison EC, Rawson KS, et al. Yoga improves balance and low-back pain, but not anxiety, in people with Parkinson's disease. *Int J Yoga Therap.* 2020;30:41–8. DOI: [10.17761/2020-D-18-00028](https://doi.org/10.17761/2020-D-18-00028).
19. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. *Mov Disord.* 2003;18:467–86. DOI: [10.1002/mds.10459](https://doi.org/10.1002/mds.10459).
20. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. *Mov Disord.* 2005;20 Suppl 11:S11–6. DOI: [10.1002/mds.20458](https://doi.org/10.1002/mds.20458).
21. Kakde N, Metri KG, Varambally S, Nagaratna R, Nagendra HR. Development and validation of a yoga module for Parkinson disease. *J Complement Integr Med.* 2017;14. DOI: [10.1515/jcim-2015-0112](https://doi.org/10.1515/jcim-2015-0112).
22. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). *Mov Disord.* 1992;7:2–13. DOI: [10.1002/mds.870070103](https://doi.org/10.1002/mds.870070103).
23. Rossini PM, Burke D, Chen R, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. *Clin Neurophysiol.* 2015;126:1071–107. DOI: [10.1016/j.clinph.2015.02.001](https://doi.org/10.1016/j.clinph.2015.02.001).
24. Agrawal A, Bhattacharya A, Kamble N, et al. Effect of lumbar drainage on cortical excitability in normal pressure hydrocephalus. *Can J Neurol Sci.* 2021;48:253–8. DOI: [10.1017/cjn.2020.169](https://doi.org/10.1017/cjn.2020.169).
25. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. *Mov Disord.* 2006;21:1200–7. DOI: [10.1002/mds.20914](https://doi.org/10.1002/mds.20914).
26. Colgrove YS, Sharma N. Effect of yoga on motor function in people with Parkinson's disease: a randomized, controlled pilot study. *J Yoga Phys Ther.* 2012;8[1]:74–9. DOI: [10.4103/0973-6131.146070](https://doi.org/10.4103/0973-6131.146070).
27. Cherup NP, Strand KL, Lucchi L, Wooten SV, Luca C, Signorile JF. Yoga meditation enhances proprioception and balance in individuals diagnosed with Parkinson's disease. *Percept Mot Skills.* 2021;128:304–23. DOI: [10.1177/0031512520945085](https://doi.org/10.1177/0031512520945085).
28. Khuzema A, Brammatha A, Arul Selvan V. Effect of home-based Tai Chi, Yoga or conventional balance exercise on functional balance and mobility among persons with idiopathic Parkinson's disease: An experimental study. *Hong Kong Physiother J.* 2020;40:39–49. DOI: [10.1142/S1013702520500055](https://doi.org/10.1142/S1013702520500055).
29. Elangovan N, Cheung C, Mahnan A, Wyman JF, Tuite P, Konczak J. Hatha yoga training improves standing balance but not gait in Parkinson's disease. *Sports Med Health Sci.* 2020;2:80–8. DOI: [10.1016/j.smhs.2020.05.005](https://doi.org/10.1016/j.smhs.2020.05.005).
30. Sharma NK, Robbins K, Wagner K, Colgrove YM. A randomized controlled pilot study of the therapeutic effects of yoga in people with Parkinson's disease. *Int J Yoga.* 2015;8:74–9. DOI: [10.4103/0973-6131.146070](https://doi.org/10.4103/0973-6131.146070).
31. Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. *J Neurol.* 2001; 248:950–8. DOI: [10.1007/s004150170047](https://doi.org/10.1007/s004150170047).
32. Lin F, Wu D, Lin C, et al. Pedunculopontine nucleus deep brain stimulation improves gait disorder in Parkinson's disease: a systematic review and meta-analysis. *Neurochem Res.* 2020;45:709–19. DOI: [10.1007/s11064-020-02962-y](https://doi.org/10.1007/s11064-020-02962-y).
33. Ziemann U. Pharmacological-transcranial magnetic stimulation studies of motor excitability. *Handb Clin Neurol.* 2013;116:387–97. DOI: [10.1016/B978-0-444-53497-2.00032-2](https://doi.org/10.1016/B978-0-444-53497-2.00032-2).
34. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. *Lancet Neurol.* 2003;2:145–56. DOI: [10.1016/s1474-4422\(03\)00321-1](https://doi.org/10.1016/s1474-4422(03)00321-1).
35. Huang L, Ren Y, Zeng Z, et al. Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson's disease monkeys. *BMC Neurosci.* 2019;20:42. DOI: [10.1186/s12868-019-0522-8](https://doi.org/10.1186/s12868-019-0522-8).
36. van Nuland AJM, den Ouden HEM, Zach H, et al. GABAergic changes in the thalamocortical circuit in Parkinson's disease. *Hum Brain Mapp.* 2020;41:1017–29. DOI: [10.1002/hbm.24857](https://doi.org/10.1002/hbm.24857).
37. O'Gorman Tuura RL, Baumann CR, Baumann-Vogel H. Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease. *Front Neurol.* 2018;9:806. DOI: [10.3389/fneur.2018.00806](https://doi.org/10.3389/fneur.2018.00806).
38. Kamble N, Bhattacharya A, Hegde S, et al. Cortical excitability changes as a marker of cognitive impairment in Parkinson's disease. *Behav Brain Res.* 2022;422:113733. DOI: [10.1016/j.bbr.2022.113733](https://doi.org/10.1016/j.bbr.2022.113733).
39. van Aalst J, Ceccarini J, Demyttenaere K, Sunaert S, Van Laere K. What has neuroimaging taught us on the neurobiology of yoga? A review. *Front Integr Neurosci.* 2020;14:34. DOI: [10.3389/fnint.2020.00034](https://doi.org/10.3389/fnint.2020.00034).
40. Pasman EP, McKeown MJ, Garg S, et al. Brain connectivity during simulated balance in older adults with and without Parkinson's disease. *Neuroimage Clin.* 2021;30:102676. DOI: [10.1016/j.nicl.2021.102676](https://doi.org/10.1016/j.nicl.2021.102676).
41. Wittenberg E, Thompson J, Nam CS, Franz JR. Neuroimaging of human balance control: a systematic review. *Front Hum Neurosci.* 2017;11:170. DOI: [10.3389/fnhum.2017.00170](https://doi.org/10.3389/fnhum.2017.00170).
42. Ni M, Signorile JF, Mooney K, et al. Comparative effect of power training and high-speed yoga on motor function in older patients with Parkinson disease. *Arch Phys Med Rehabil.* 2016;97:345–354.e15. DOI: [10.1016/j.apmr.2015.10.095](https://doi.org/10.1016/j.apmr.2015.10.095).
43. Cheung C, Bhimani R, Wyman JF, et al. Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson's disease: a pilot randomized controlled trial. *Pilot Feasibility Stud.* 2018;4:162. DOI: [10.1186/s40814-018-0355-8](https://doi.org/10.1186/s40814-018-0355-8).
44. Cilia R, Cereda E, Akpalu A, et al. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa. *Brain.* 2020;143:2490–501. DOI: [10.1093/brain/awaa181](https://doi.org/10.1093/brain/awaa181).